Cargando…

Serum Phosphate as a Risk Factor for Cardiovascular Events in People with and without Chronic Kidney Disease: A Large Community Based Cohort Study

BACKGROUND: Serum phosphate is a known risk factor for cardiovascular events and mortality in people with chronic kidney disease (CKD), however data on the association of these outcomes with serum phosphate in the general population are scarce. We investigate this relationship in people with and wit...

Descripción completa

Detalles Bibliográficos
Autores principales: McGovern, Andrew Peter, de Lusignan, Simon, van Vlymen, Jeremy, Liyanage, Harshana, Tomson, Charles Richard, Gallagher, Hugh, Rafiq, Meena, Jones, Simon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769279/
https://www.ncbi.nlm.nih.gov/pubmed/24040373
http://dx.doi.org/10.1371/journal.pone.0074996
_version_ 1782283958341337088
author McGovern, Andrew Peter
de Lusignan, Simon
van Vlymen, Jeremy
Liyanage, Harshana
Tomson, Charles Richard
Gallagher, Hugh
Rafiq, Meena
Jones, Simon
author_facet McGovern, Andrew Peter
de Lusignan, Simon
van Vlymen, Jeremy
Liyanage, Harshana
Tomson, Charles Richard
Gallagher, Hugh
Rafiq, Meena
Jones, Simon
author_sort McGovern, Andrew Peter
collection PubMed
description BACKGROUND: Serum phosphate is a known risk factor for cardiovascular events and mortality in people with chronic kidney disease (CKD), however data on the association of these outcomes with serum phosphate in the general population are scarce. We investigate this relationship in people with and without CKD in a large community-based population. METHODS: Three groups from an adult cohort of the Quality Improvement in Chronic Kidney Disease (QICKD) cluster randomised trial (ISRCTN56023731) were followed over a period of 2.5 years: people with normal renal function (N = 24,184), people with CKD stages 1–2 (N = 20,356), and people with CKD stages 3–5 (N = 13,292). We used a multilevel logistic regression model to determine the association between serum phosphate, in these groups, and a composite outcome of all-cause mortality, cardiovascular events, and advanced coronary artery disease. We adjusted for known cardiovascular risk factors. FINDINGS: Higher phosphate levels were found to correlate with increased cardiovascular risk. In people with normal renal function and CKD stages 1–2, Phosphate levels between 1.25 and 1.50 mmol/l were associated with increased cardiovascular events; odds ratio (OR) 1.36 (95% CI 1.06–1.74; p = 0.016) in people with normal renal function and OR 1.40 (95% CI 1.09–1.81; p = 0.010) in people with CKD stages 1–2. Hypophosphatemia (<0.75 mmol/l) was associated with fewer cardiovascular events in people with normal renal function; OR 0.59 (95% CI 0.36–0.97; p = 0.049). In people with CKD stages 3–5, hyperphosphatemia (>1.50 mmol/l) was associated with increased cardiovascular risk; OR 2.34 (95% CI 1.64–3.32; p<0.001). Other phosphate ranges were not found to have a significant impact on cardiovascular events in people with CKD stages 3–5. CONCLUSIONS: Serum phosphate is associated with cardiovascular events in people with and without CKD. Further research is required to determine the mechanisms underlying these associations.
format Online
Article
Text
id pubmed-3769279
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-37692792013-09-13 Serum Phosphate as a Risk Factor for Cardiovascular Events in People with and without Chronic Kidney Disease: A Large Community Based Cohort Study McGovern, Andrew Peter de Lusignan, Simon van Vlymen, Jeremy Liyanage, Harshana Tomson, Charles Richard Gallagher, Hugh Rafiq, Meena Jones, Simon PLoS One Research Article BACKGROUND: Serum phosphate is a known risk factor for cardiovascular events and mortality in people with chronic kidney disease (CKD), however data on the association of these outcomes with serum phosphate in the general population are scarce. We investigate this relationship in people with and without CKD in a large community-based population. METHODS: Three groups from an adult cohort of the Quality Improvement in Chronic Kidney Disease (QICKD) cluster randomised trial (ISRCTN56023731) were followed over a period of 2.5 years: people with normal renal function (N = 24,184), people with CKD stages 1–2 (N = 20,356), and people with CKD stages 3–5 (N = 13,292). We used a multilevel logistic regression model to determine the association between serum phosphate, in these groups, and a composite outcome of all-cause mortality, cardiovascular events, and advanced coronary artery disease. We adjusted for known cardiovascular risk factors. FINDINGS: Higher phosphate levels were found to correlate with increased cardiovascular risk. In people with normal renal function and CKD stages 1–2, Phosphate levels between 1.25 and 1.50 mmol/l were associated with increased cardiovascular events; odds ratio (OR) 1.36 (95% CI 1.06–1.74; p = 0.016) in people with normal renal function and OR 1.40 (95% CI 1.09–1.81; p = 0.010) in people with CKD stages 1–2. Hypophosphatemia (<0.75 mmol/l) was associated with fewer cardiovascular events in people with normal renal function; OR 0.59 (95% CI 0.36–0.97; p = 0.049). In people with CKD stages 3–5, hyperphosphatemia (>1.50 mmol/l) was associated with increased cardiovascular risk; OR 2.34 (95% CI 1.64–3.32; p<0.001). Other phosphate ranges were not found to have a significant impact on cardiovascular events in people with CKD stages 3–5. CONCLUSIONS: Serum phosphate is associated with cardiovascular events in people with and without CKD. Further research is required to determine the mechanisms underlying these associations. Public Library of Science 2013-09-10 /pmc/articles/PMC3769279/ /pubmed/24040373 http://dx.doi.org/10.1371/journal.pone.0074996 Text en © 2013 McGovern et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
McGovern, Andrew Peter
de Lusignan, Simon
van Vlymen, Jeremy
Liyanage, Harshana
Tomson, Charles Richard
Gallagher, Hugh
Rafiq, Meena
Jones, Simon
Serum Phosphate as a Risk Factor for Cardiovascular Events in People with and without Chronic Kidney Disease: A Large Community Based Cohort Study
title Serum Phosphate as a Risk Factor for Cardiovascular Events in People with and without Chronic Kidney Disease: A Large Community Based Cohort Study
title_full Serum Phosphate as a Risk Factor for Cardiovascular Events in People with and without Chronic Kidney Disease: A Large Community Based Cohort Study
title_fullStr Serum Phosphate as a Risk Factor for Cardiovascular Events in People with and without Chronic Kidney Disease: A Large Community Based Cohort Study
title_full_unstemmed Serum Phosphate as a Risk Factor for Cardiovascular Events in People with and without Chronic Kidney Disease: A Large Community Based Cohort Study
title_short Serum Phosphate as a Risk Factor for Cardiovascular Events in People with and without Chronic Kidney Disease: A Large Community Based Cohort Study
title_sort serum phosphate as a risk factor for cardiovascular events in people with and without chronic kidney disease: a large community based cohort study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3769279/
https://www.ncbi.nlm.nih.gov/pubmed/24040373
http://dx.doi.org/10.1371/journal.pone.0074996
work_keys_str_mv AT mcgovernandrewpeter serumphosphateasariskfactorforcardiovasculareventsinpeoplewithandwithoutchronickidneydiseasealargecommunitybasedcohortstudy
AT delusignansimon serumphosphateasariskfactorforcardiovasculareventsinpeoplewithandwithoutchronickidneydiseasealargecommunitybasedcohortstudy
AT vanvlymenjeremy serumphosphateasariskfactorforcardiovasculareventsinpeoplewithandwithoutchronickidneydiseasealargecommunitybasedcohortstudy
AT liyanageharshana serumphosphateasariskfactorforcardiovasculareventsinpeoplewithandwithoutchronickidneydiseasealargecommunitybasedcohortstudy
AT tomsoncharlesrichard serumphosphateasariskfactorforcardiovasculareventsinpeoplewithandwithoutchronickidneydiseasealargecommunitybasedcohortstudy
AT gallagherhugh serumphosphateasariskfactorforcardiovasculareventsinpeoplewithandwithoutchronickidneydiseasealargecommunitybasedcohortstudy
AT rafiqmeena serumphosphateasariskfactorforcardiovasculareventsinpeoplewithandwithoutchronickidneydiseasealargecommunitybasedcohortstudy
AT jonessimon serumphosphateasariskfactorforcardiovasculareventsinpeoplewithandwithoutchronickidneydiseasealargecommunitybasedcohortstudy